TY - JOUR
T1 - C-peptide immunoreactivity index is associated with improvement of HbA1c
T2 - 2-Year follow-up of sitagliptin use in patients with type 2 diabetes
AU - Nishimura, Takeshi
AU - Meguro, Shu
AU - Sekioka, Risa
AU - Tanaka, Karin
AU - Saisho, Yoshifumi
AU - Irie, Junichiro
AU - Tanaka, Masami
AU - Kawai, Toshihide
AU - Itoh, Hiroshi
N1 - Funding Information:
Hiroshi Itoh and Shu Meguro received a scholarship grant from MSD. All the other authors have no conflict of interest.
Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4% [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4% [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8% [57. ±. 9. mmol/mol], 7.3. ±. 0.9% [57. ±. 9. mmol/mol], 7.4. ±. 0.9% [58. ±. 10. mmol/mol], 7.1. ±. 0.8% [55. ±. 9. mmol/mol], and 7.3. ±. 0.9% [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0%, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.
AB - Aims: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]. ×. 100). Methods: The inclusion criteria for DPP-4 inhibitor-naive outpatients with type 2 diabetes (. n=. 285) were: continuation of sitagliptin for ≥700 days from initial administration and measurement of HbA1c, serum CPR, and plasma glucose levels at 0, 3, 6, 12, 18, and 24 months after sitagliptin initiation. Logistic regression analyses determined the factors contributing to the response to sitagliptin, based on responder (δHbA1c ≤-0.4% [≤-4. mmol/mol]) and non-responder (δHbA1c >-0.4% [>-4. mmol/mol]) groups. Results: The HbA1c level decreased and CPR index increased from baseline to 3, 6, 12, 18, and 24 months after the start of sitagliptin administration (HbA1c: 7.4. ±. 0.8% [57. ±. 9. mmol/mol], 7.3. ±. 0.9% [57. ±. 9. mmol/mol], 7.4. ±. 0.9% [58. ±. 10. mmol/mol], 7.1. ±. 0.8% [55. ±. 9. mmol/mol], and 7.3. ±. 0.9% [57. ±. 10. mmol/mol], respectively, all P<. 0.001 vs. baseline [8.0. ±. 1.0%, 64. ±. 11. mmol/mol] and CPR index: 1.69. ±. 0.96, 1.71. ±. 1.10, 1.62. ±. 0.96, 1.64. ±. 0.92, and 1.66. ±. 0.96, respectively, all P<. 0.05 vs. baseline [1.47. ±. 0.81]). Higher baseline HbA1c level, shorter diabetes duration, and greater CPR index increase after sitagliptin administration were associated with the response to sitagliptin. Conclusions: Our results suggest that sitagliptin improves glycaemic control via an improved intrinsic insulin response.
KW - C-peptide
KW - Haemoglobin A1c protein
KW - Human
KW - Long-term effect
KW - Sitagliptin
UR - http://www.scopus.com/inward/record.url?scp=84930180756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930180756&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2015.02.031
DO - 10.1016/j.diabres.2015.02.031
M3 - Article
C2 - 25795273
AN - SCOPUS:84930180756
SN - 0168-8227
VL - 108
SP - 441
EP - 447
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
IS - 3
ER -
